SINGAPORE, Oct. 22, 2019 /PRNewswire/ — Zuellig Pharma, a leading healthcare service provider in Asia, is pleased to announce two new strategic partnerships with Eli Lilly and Company (Lilly) to market, sell and distribute the healthcare manufacturer’s existing and new products in Malaysia and Thailand.
Lilly is a global healthcare company with a heritage of more than 140 years, committed to creating high-quality life-changing medicines that meet real needs to make life better for people around the world. In both Malaysia and Thailand, it has proudly served healthcare professionals and their patients with innovative medicines in the areas of diabetes, oncology, men’s health, bone health, diseases impacting the central nervous system and immunology with several leading brands in the market.
"We are excited to represent Lilly’s innovative portfolio of products to the communities in both countries. Our team is also committed to launch new products from Lilly to meet the evolving healthcare needs in the region and to ensure patients will get access to the healthcare they need," said John Graham, SVP Commercial Solutions Zuellig Pharma.
As one of the largest healthcare services groups in Asia, Zuellig Pharma aims to continue establishing new strategic alliances to deliver on the promise of making healthcare more accessible in the region. Under this new business model, Zuellig Pharma intends to grow Lilly’s innovative products across a number of diverse therapeutic categories. In doing so, Zuellig Pharma will develop world class capabilities in Diabetes, Oncology, Immunology and CNS.
"We are truly excited about commencing a strategic partnership with Zuellig Pharma in several ASEAN markets. Zuellig Pharma is a partner that shares our goal of developing a diverse and inclusive workforce delivering high performance with high integrity. Our teams in Lilly Malaysia and Lilly Thailand will work closely with Zuellig Pharma’s leadership to ensure that we continue to bring new innovative products for the benefit of patients in this region," said Rehan Saghir, General Manager for Lilly ASEAN.
Together, Zuellig Pharma and Lilly look forward to continue to serve and improve the lives of patients with Lilly’s existing and new innovations in Diabetes, Oncology, Immunology and Pain in the years to come.
About Zuellig Pharma
Zuellig Pharma is one of the largest healthcare services groups in Asia and our purpose is to make healthcare more accessible. We provide world-class distribution, digital and commercial services to support the growing healthcare needs in this region. The company was started almost a hundred years ago and has grown to become a US$13 billion business covering 13 markets with over 13,000 employees. Our people serve over 350,000 medical facilities and work with over 1,000 clients, including the top 20 pharmaceutical companies in the world.
More recently, we launched our Zuellig Health Solutions Innovation Centre to develop new services and address some pressing healthcare needs in Asia. Since then, our teams have been focused on creating data, digital and disease management solutions, supporting patients with chronic conditions and helping payors manage healthcare costs.
About Eli Lilly and Company
Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.